{"id":"camrelizumab-and-chemotherapy","safety":{"commonSideEffects":[{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Immune-related adverse events (pneumonitis, hepatitis, colitis)"},{"rate":null,"effect":"Decreased hemoglobin"},{"rate":null,"effect":"Decreased neutrophils"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Camrelizumab binds to programmed death receptor-1 (PD-1) on T cells, preventing interaction with PD-L1/PD-L2 ligands on tumor cells and reversing immune exhaustion. This checkpoint blockade restores cytotoxic T-cell function. When combined with chemotherapy, the chemotherapy provides direct cytotoxic effects while camrelizumab amplifies the immune response, creating a synergistic anti-tumor effect.","oneSentence":"Camrelizumab is a PD-1 inhibitor that blocks immune checkpoint signaling to restore anti-tumor T-cell activity, used in combination with chemotherapy to enhance cancer cell killing.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:04:48.093Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Nasopharyngeal carcinoma in combination with chemotherapy"},{"name":"Hepatocellular carcinoma in combination with chemotherapy"},{"name":"Esophageal squamous cell carcinoma in combination with chemotherapy"}]},"trialDetails":[{"nctId":"NCT07320586","phase":"PHASE2","title":"Carilizumab and Albumin Paclitaxel for Second-line Treatment of Advanced Gastric Cancer","status":"RECRUITING","sponsor":"Shandong Tumor Hospital","startDate":"2021-03-01","conditions":"Gastric Cancer, Second-line Therapy","enrollment":40},{"nctId":"NCT07471815","phase":"PHASE2","title":"Camrelizumab Plus Risedronate and Chemotherapy for Triple-Negative Breast Cancer: An Exploratory Clinical Study on Mechanisms and Efficacy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Harbin Medical University","startDate":"2026-03-04","conditions":"Breast Cancer Triple Negative Breast Cancer","enrollment":30},{"nctId":"NCT06239727","phase":"PHASE3","title":"Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-03-01","conditions":"Nasopharyngeal Carcinoma","enrollment":593},{"nctId":"NCT04928807","phase":"PHASE3","title":"Short-Course Radiotherapy Followed by Neoadjuvant Chemotherapy and Camrelizumab in Locally Advanced Rectal Cancer (UNION)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2021-07-20","conditions":"Rectal Cancer","enrollment":231},{"nctId":"NCT07432087","phase":"PHASE3","title":"Camrelizumab Combined With EGFR Monoclonal Antibody or Chemotherapy for Perioperative Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Yue He, MD","startDate":"2026-02-01","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":246},{"nctId":"NCT06802757","phase":"PHASE2","title":"Posaconazole Plus PD-1 Inhibitors and Chemotherapy vs PD-1 Inhibitors and Chemotherapy in Neoadjuvant Therapy for Triple Negative Breast Cancer","status":"RECRUITING","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2025-05-01","conditions":"Breast Cancer","enrollment":72},{"nctId":"NCT07397442","phase":"PHASE2","title":"Short-Course Radiotherapy Combined With Chemotherapy and Immunotherapy in Mid-Low Locally Advanced Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Beijing Friendship Hospital","startDate":"2026-03-01","conditions":"Rectal Cancer, Adenocarcinoma, Rectal Cancer Stage II, Rectal Cancer Stage III","enrollment":19},{"nctId":"NCT07401199","phase":"","title":"Multimodal AI for Predicting Response to Neoadjuvant Immunotherapy in Gastric Cancer (PRISM-GC)","status":"NOT_YET_RECRUITING","sponsor":"Qun Zhao","startDate":"2026-02-05","conditions":"Gastric Cancer (GC), Locally Advanced Gastric Cancer","enrollment":2000},{"nctId":"NCT05139095","phase":"PHASE2","title":"Camrelizumab Plus Apatinib in Patients With High-risk Gestational Trophoblastic Neoplasia","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2022-01-27","conditions":"Gestational Trophoblastic Neoplasia","enrollment":70},{"nctId":"NCT07332247","phase":"PHASE2","title":"PD-1 Inhibitor Plus Chemotherapy Followed by Immediate Versus Selective Re-irradiation for Locally Advanced Recurrent NPC","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-02-03","conditions":"Nasopharangeal Cancer, Recurrent Nasopharynx Carcinoma","enrollment":94},{"nctId":"NCT06631326","phase":"","title":"HAIC in Combination With PD-1 Inhibitors and Lenvatinib for High Tumor Burden Advanced HCC (CHANCE2416)","status":"COMPLETED","sponsor":"First Hospital of China Medical University","startDate":"2021-01-01","conditions":"HCC - Hepatocellular Carcinoma, Hepatic Arterial Infusion Chemotherapy, BCLC Stage C Hepatocellular Carcinoma","enrollment":244},{"nctId":"NCT05198609","phase":"PHASE3","title":"Camrelizumab, Apatinib Plus HAIC Versus Camrelizumab and Apatinib for HCC With Portal Vein Invasion: a Randomized Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2022-01-17","conditions":"Hepatocellular Carcinoma","enrollment":214},{"nctId":"NCT07328009","phase":"PHASE2","title":"A Platform Trial for Personalized and Adaptive Therapies in Hepatocellular Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2026-01-25","conditions":"Hepato Cellular Carcinoma (HCC)","enrollment":350},{"nctId":"NCT04342910","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2020-09-21","conditions":"Gastric Cancer","enrollment":550},{"nctId":"NCT05524168","phase":"PHASE2","title":"SBRT Combined With PD-1 Antibody and Chemotherapy in Oligometastatic Nasopharyngeal Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2022-11-25","conditions":"Nasopharyngeal Carcinoma","enrollment":41},{"nctId":"NCT07312578","phase":"PHASE2","title":"Nimotuzumab,Camrelizumab, and Neoadjuvant Chemotherapy（nCT） in the Treatment of Esophageal Squamous Cell Carcinoma","status":"ENROLLING_BY_INVITATION","sponsor":"Peking University","startDate":"2025-11-01","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":48},{"nctId":"NCT07267806","phase":"PHASE3","title":"Camrelizumab and Apatinib With or Without FOLFOX Chemotherapy for Advanced HCC","status":"RECRUITING","sponsor":"Linhui Peng","startDate":"2025-10-31","conditions":"Hepato Cellular Carcinoma (HCC), Chemotherapy Effect","enrollment":326},{"nctId":"NCT06866951","phase":"PHASE2, PHASE3","title":"A Clinical Study Comparing Chemotherapy Combined With PD-1 Inhibitor Versus Concurrent Chemoradiotherapy in Cervical Cancer Patients With Positive Lymph Nodes After Surgery: A Multicenter Randomized Controlled Clinical Trial","status":"WITHDRAWN","sponsor":"Women's Hospital School Of Medicine Zhejiang University","startDate":"2025-03-01","conditions":"Cervical Cancers","enrollment":""},{"nctId":"NCT06817525","phase":"PHASE2","title":"Nab-P+Cb+PD1 Inhibitors as Neoadjuvant Therapy for Early TNBC","status":"RECRUITING","sponsor":"Henan Cancer Hospital","startDate":"2024-11-06","conditions":"Triple-negative Breast Cancer","enrollment":64},{"nctId":"NCT06561308","phase":"PHASE2","title":"Clinical Efficacy Study of PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Advanced Endometrial Cancer","status":"RECRUITING","sponsor":"Women's Hospital School Of Medicine Zhejiang University","startDate":"2025-09-01","conditions":"Endometrioid Endometrial Cancer","enrollment":39},{"nctId":"NCT07251062","phase":"PHASE2, PHASE3","title":"A Study of SYS6010, Enlonstobart, and Chemotherapy for First-Line Treatment of Esophageal Squamous Cell Carcinoma.","status":"NOT_YET_RECRUITING","sponsor":"CSPC Megalith Biopharmaceutical Co.,Ltd.","startDate":"2025-12-30","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":737},{"nctId":"NCT07235319","phase":"PHASE3","title":"PD-1 Inhibitor Plus Chemotherapy Followed by Immediate Versus Salvage Locoregional Radiotherapy in De Novo Metastatic NPC","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-11-20","conditions":"Nasopharangeal Cancer, Distant Metastasis","enrollment":260},{"nctId":"NCT07236320","phase":"NA","title":"Neoadjuvant Immunochemotherapy vs Chemoradiotherapy in ESCC","status":"COMPLETED","sponsor":"Yongtao Han","startDate":"2018-03-01","conditions":"Esophageal Squamous Cell Carcinoma (ESCC)","enrollment":200},{"nctId":"NCT06869226","phase":"PHASE2","title":"A Multicenter Phase II Clinical Study of Neoadjuvant Use of Camrelizumab in Combination With Chemotherapy for Organ Preservation in Esophageal Cancer","status":"RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2025-04-30","conditions":"Esophageal Cancer","enrollment":283},{"nctId":"NCT07190027","phase":"PHASE1, PHASE2","title":"Immunodynamics-Guided Optimization of Individualized Immunochemotherapy in Advanced Driver-Negative NSCLC: A Randomized Trial","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital of Wenzhou Medical University","startDate":"2025-11","conditions":"Advanced Non-Small Cell Lung Cancer (NSCLC)","enrollment":246},{"nctId":"NCT04619433","phase":"PHASE3","title":"A Study to Evaluate SHR-1210 in Combination With Famitinib Plus Chemotherapy in Subjects With NSCLC.","status":"TERMINATED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2021-02-01","conditions":"Non-squamous Non-small-cell Lung Cancer","enrollment":48},{"nctId":"NCT07181850","phase":"","title":"Predicting Pathological Complete Response in Esophageal Squamous Cell Carcinoma Using a Multimodal Model Integrating Clinical, Radiomics, and Deep Learning Features","status":"COMPLETED","sponsor":"Nanjing Medical University","startDate":"2019-01-01","conditions":"Esophageal Squamous Cell Carcinoma, Pathological Complete Response","enrollment":363},{"nctId":"NCT06145308","phase":"PHASE2","title":"Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing","status":"RECRUITING","sponsor":"Peking Union Medical College","startDate":"2023-08-15","conditions":"Salivary Gland Carcinoma, Precision Therapy","enrollment":39},{"nctId":"NCT07161791","phase":"PHASE1, PHASE2","title":"Camrelizumab, Pirfenidone, and Chemotherapy in the Treatment of Advanced Triple-Negative Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Harbin Medical University","startDate":"2025-09-15","conditions":"Breast Cancer, Triple Negative Breast Cancer (TNBC)","enrollment":12},{"nctId":"NCT07107217","phase":"PHASE2","title":"Camrelizumab in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-negative Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Blokhin's Russian Cancer Research Center","startDate":"2025-08","conditions":"Breast Cancer","enrollment":40},{"nctId":"NCT07057089","phase":"PHASE2","title":"Involved-field Radiotherapy-TNT Combined With PD-1 Inhibitor for pMMR Locally Advanced Rectal Cancer (Neo-Field I)","status":"RECRUITING","sponsor":"Hebei Medical University Fourth Hospital","startDate":"2025-07-01","conditions":"Locally Advanced Rectal Cancer","enrollment":90},{"nctId":"NCT06323382","phase":"","title":"Locoregional Therapy Combined With Bevacizumab and PD1/L1 Inhibitor in Advanced Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2021-01-01","conditions":"Advanced Hepatocellular Carcinoma, Anti-PD1/PDL1 Antibody, Bevacizumab","enrollment":240},{"nctId":"NCT05673577","phase":"PHASE2","title":"Camrelizumab in Combination With Cetuximab and Chemotherapy for Relapsed/Metastatic HNSCC Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fudan University","startDate":"2023-03-22","conditions":"Squamous Cell Carcinoma of Head and Neck","enrollment":40},{"nctId":"NCT06896422","phase":"PHASE1","title":"Randomized Trial of Glutathione With Anti-PD-1 and Chemotherapy in Advanced NSCLC","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Zhengzhou University","startDate":"2025-06-01","conditions":"Non-Small Cell Lung Cancer, Chemotherapy, PD1 Antibody","enrollment":80},{"nctId":"NCT04680988","phase":"PHASE2","title":"A Study of SHR-1210± SHR-1020 Versus Chemotherapy in Patients With Recurrent or Metastatic Cervical Cancer","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2021-04-05","conditions":"Recurrent or Metastatic Cervical Cancer","enrollment":194},{"nctId":"NCT05156970","phase":"PHASE2","title":"Camrelizumab in Combination With Chemotherapy or Apatinib Mesylate as First-Line Treatment for R/M HNSCC","status":"COMPLETED","sponsor":"Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University","startDate":"2021-06-24","conditions":"Recurrent Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma","enrollment":81},{"nctId":"NCT07059949","phase":"PHASE2","title":"Short Course Radiotherapy Followed by CAPOX and Carrilizumab and Bevacizumab or Cetuximab for the Initial Treatment of Unresectable Metastatic Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2025-06-30","conditions":"Unresectable Metastatic Rectal Cancer, CAPOX, Combination of Radioimmunotherapy","enrollment":80},{"nctId":"NCT07054086","phase":"","title":"Patient Derived Organoids (PDOs) to Observe the Clinical Consistency of Personalized Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2025-03-01","conditions":"Esophageal Cancer","enrollment":30},{"nctId":"NCT07053215","phase":"NA","title":"Efficacy of Argon-Helium Cryoablation Plus PD-1 Inhibitors in NSCLC","status":"COMPLETED","sponsor":"The First Hospital of Hebei Medical University","startDate":"2020-12-01","conditions":"Non-small Cell Lung Cancer (NSCLC)","enrollment":60},{"nctId":"NCT03777124","phase":"PHASE2","title":"Phase II Study of SHR-1210(Anti-PD-1 Antibody) Combination With Apatinib Versus Pemetrexed and Carboplatin in Subjects With KRAS Mutant Stage IV Non-squamous Non-small Cell Lung Cancer","status":"TERMINATED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2019-07-11","conditions":"NSCLC Stage IV, KRAS Gene Mutation, PD-1 Antibody","enrollment":25},{"nctId":"NCT06811844","phase":"PHASE2","title":"Two-cycle and Three-cycle Induction Therapy With Modified TPF Regimen Combined and Camrelizumab for LANPC","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Xiamen University","startDate":"2025-02-25","conditions":"Nasopharyngeal Neoplasms, PD-1 Inhibitor, Induction Therapy","enrollment":208},{"nctId":"NCT06435260","phase":"PHASE2","title":"Hypofractionated Radiotherapy +Chemotherapy+ Camrelizumab as Neoadjuvant Therapy for Pancreatic Cancer","status":"RECRUITING","sponsor":"Hebei Medical University Fourth Hospital","startDate":"2024-08-01","conditions":"Pancreatic Cancer","enrollment":30},{"nctId":"NCT07035860","phase":"","title":"Efficacy and Safety of Chemoimmunotherapy and Carbon Ion Radiotherapy in Unresectable Locally Advanced Non-small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Ji Yongling","startDate":"2025-06-16","conditions":"Carbon Ion Radiotheray","enrollment":34},{"nctId":"NCT04625803","phase":"PHASE2","title":"Neoadjuvant Therapy for Locally Advanced Colon Cancer","status":"COMPLETED","sponsor":"Zhejiang University","startDate":"2021-01-04","conditions":"Colon Cancer, Neoadjuvant Therapy","enrollment":64},{"nctId":"NCT07016737","phase":"PHASE3","title":"Immunochemotherapy ± Salvage Chemoradiation for Local Recurrence of Esophageal Squamous Cell Carcinoma After Definitive Chemoradiotherapy","status":"ENROLLING_BY_INVITATION","sponsor":"Ye jinjun","startDate":"2024-08-01","conditions":"Esophageal Squamous Cell Carcinoma (ESCC)","enrollment":79},{"nctId":"NCT07015489","phase":"PHASE2","title":"Concurrent Radiotherapy Following Induction Chemoimmunotherapy for Locally Advanced Esophageal Cancer","status":"COMPLETED","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2022-01-01","conditions":"ESCC","enrollment":44},{"nctId":"NCT06818097","phase":"","title":"Efficacy of Target - Immunotherapy and XELOX Chemotherapy for Advanced HCC","status":"COMPLETED","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2021-10-01","conditions":"Advanced HCC, Systemic Therapy, Chemotherapy","enrollment":68},{"nctId":"NCT06889688","phase":"PHASE3","title":"Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2025-04-01","conditions":"Breast Cancer Stage IV","enrollment":246},{"nctId":"NCT06926179","phase":"","title":"Safety, Efficacy, and Survival Outcomes of Neoadjuvant/Induction Immunotherapy in Surgical and Radiotherapeutic Management of Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2024-12-01","conditions":"Lung Cancer (NSCLC), Neoadjuvant Immunotherapy, Radiotherapy","enrollment":500},{"nctId":"NCT06901622","phase":"PHASE2","title":"Camrelizumab and Chemotherapy With or Without Anlotinib as First-line Treatment for Advanced Gallbladder Cancer and Extrahepatic Cholangiocarcinoma","status":"ENROLLING_BY_INVITATION","sponsor":"The First Affiliated Hospital of Zhengzhou University","startDate":"2024-11-08","conditions":"Gallbladder Cancer and Extrahepatic Cholangiocarcinoma","enrollment":50},{"nctId":"NCT05713994","phase":"","title":"Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Ze-yang Ding, MD","startDate":"2020-05-19","conditions":"Hepatocellular Carcinoma Non-resectable","enrollment":300},{"nctId":"NCT06288360","phase":"PHASE2","title":"Neoadjuvant Immunochemotherapy in PD-L1-negative LACC","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2024-09-12","conditions":"Cervical Cancer, Locally Advanced Cervical Cancer, PD-L1 Negative","enrollment":40},{"nctId":"NCT04510064","phase":"PHASE2","title":"Conversion Effects of PD-1 Antibody Camrelizumab Combined With Nab-POF Regimen Chemotherpy in Patients With Initially Unresectable Locally Advanced or Limited Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma：FDZL-GC001 Trial","status":"COMPLETED","sponsor":"Fudan University","startDate":"2021-01-06","conditions":"Metastatic Gastric Cancer, Locally Advanced Gastric Adenocarcinoma, Gastric Cancer Adenocarcinoma Metastatic","enrollment":40},{"nctId":"NCT06849492","phase":"PHASE2","title":"HIM Typing Guides the Treatment of Advanced First-Line Triple-Negative Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-04-01","conditions":"Advanced Triple Negative Breast Cancer","enrollment":120},{"nctId":"NCT06796803","phase":"PHASE2, PHASE3","title":"Camrelizumab Combined with Rivoceranib and Hepatic Arterial Infusion Chemotherapy (HAIC) As Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma(HCC)","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2025-02-20","conditions":"Potentially Resectable Hepatocellular Carcinoma","enrollment":398},{"nctId":"NCT06333561","phase":"","title":"HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2021-01-01","conditions":"Hepatocellular Carcinoma, Lenvatinib, PD-1 Inhibitor","enrollment":300},{"nctId":"NCT04649476","phase":"PHASE2","title":"Neoadjuvant PD-1 Blockade in Resectable Oral Squamous Cell Carcinoma","status":"COMPLETED","sponsor":"Hospital of Stomatology, Wuhan University","startDate":"2021-03-22","conditions":"Oral Squamous Cell Carcinoma","enrollment":68},{"nctId":"NCT06759090","phase":"PHASE2","title":"Metronomic Capecitabine with Camrelizumab and Apatinib Mesylate for Treatment of Advanced Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"Zhejiang University","startDate":"2025-01-15","conditions":"Metastatic Pancreatic Carcinoma","enrollment":43},{"nctId":"NCT06669611","phase":"PHASE3","title":"Nab-TPC vs GP Combined With Camrelizumab in the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-11-27","conditions":"Nasopharyngeal Cancinoma (NPC)","enrollment":242},{"nctId":"NCT06702566","phase":"NA","title":"The Effect of Serum Ferritin in irAE","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2024-07-04","conditions":"Immune-related Adverse Event, Malignant Solid Tumors, Acute Leukemia","enrollment":1500},{"nctId":"NCT05738434","phase":"PHASE2","title":"Camrelizumab in Combination With Apatinib Mesylate Plus Short-course Chemotherapy for Advanced ESCC","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Zhengzhou University","startDate":"2023-03-02","conditions":"Esophageal Cancer by AJCC V8 Stage","enrollment":188},{"nctId":"NCT06692491","phase":"PHASE2","title":"Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS","status":"NOT_YET_RECRUITING","sponsor":"Peking University Shenzhen Hospital","startDate":"2025-01-01","conditions":"Rare Tumour","enrollment":200},{"nctId":"NCT06636591","phase":"NA","title":"Pilot Study of Neoadjuvant Chemotherapy Combined With Immunotherapy and Multimodal Thermal Therapy for HER2-negative Breast Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-11-18","conditions":"Breast Cancer Female, HER2-negative Breast Cancer","enrollment":14},{"nctId":"NCT06289062","phase":"PHASE2","title":"Neoadjuvant Chemotherapy Plus Camrelizumab for FIGO Stage IB1 Cervical Cancer","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2024-05-08","conditions":"Cervical Cancer, Neoadjuvant Chemoimmunotherapy, Fertility Preservation","enrollment":40},{"nctId":"NCT05003700","phase":"PHASE2","title":"Hepatic Arterial Infusion Combined With Lenvatinib and Camrelizumab for Unresectable Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2021-08-12","conditions":"Hepatocellular Carcinoma","enrollment":39},{"nctId":"NCT06675214","phase":"PHASE3","title":"Under Whole-course of Immunotherapy, Gradient Fractionated RT with CCT Versus CFRT with CCT for LANPC Who Achieved PR Post Induction Chemotherapy.","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-07-30","conditions":"Nasopharyngeal Carcinoma, De-escalation Therapy","enrollment":586},{"nctId":"NCT04294784","phase":"PHASE2","title":"Nab-paclitaxel Plus PD-1 Inhibitor Versus Nab-paclitaxel As Second-line Treatment in Advanced Gastric Cancer","status":"TERMINATED","sponsor":"Huazhong University of Science and Technology","startDate":"2020-04-03","conditions":"Gastric Cancer, GastroEsophageal Cancer","enrollment":58},{"nctId":"NCT06288373","phase":"PHASE2, PHASE3","title":"Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACC","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2024-04-22","conditions":"Cervical Cancer, Locally Advanced Cervical Cancer, Concurrent Chemoradiotherapy","enrollment":440},{"nctId":"NCT05043688","phase":"PHASE3","title":"Camrelizumab Plus Neoadjuvant Chemotherapy or Chemoradiotherapy Versus Chemoradiotherapy in Resectable ESCC.","status":"RECRUITING","sponsor":"Zhigang Li","startDate":"2021-09-01","conditions":"Resectable Esophageal Squamous Cell Carcinoma","enrollment":426},{"nctId":"NCT06632106","phase":"","title":"HAIC in Combination with Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Advanced HCC","status":"ACTIVE_NOT_RECRUITING","sponsor":"First Hospital of China Medical University","startDate":"2024-08-16","conditions":"Hepatic Arterial Infusion Chemotherapy, Tyrosine Kinase Inhibitor, Immune Checkpoint Inhibitors","enrollment":97},{"nctId":"NCT06632093","phase":"","title":"HAIC in Combination with PD-1 Inhibitors and Lenvatinib for Intermediate and Advanced HCC After the Failure of Systemic Therapy Recommended by BCLC","status":"RECRUITING","sponsor":"First Hospital of China Medical University","startDate":"2024-09-16","conditions":"BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma, Hepatic Arterial Infusion Chemotherapy","enrollment":84},{"nctId":"NCT06607107","phase":"PHASE2","title":"mFOLFOX7 Plus Camrelizumab and Apatinib in BCLC Stage A/B Hepatocellular Carcinoma Patients Beyond Milan Criteria","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2024-02-17","conditions":"Hepatocellular Carcinoma Non-resectable","enrollment":29},{"nctId":"NCT04515615","phase":"PHASE2","title":"Adjuvant Chemotherapy in Combination With Camrelizumab for Stage III Gastric Cancer (FOCUS-02)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Yu jiren","startDate":"2020-09-09","conditions":"Gastric Cancer Stage III","enrollment":52},{"nctId":"NCT05412589","phase":"PHASE2","title":"mFOLFOX7 Plus Camrelizumab and Apatinib for Advanced HCC","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2022-06-10","conditions":"Stage III Hepatocellular Cancer (CNLC Staging)","enrollment":35},{"nctId":"NCT05554276","phase":"PHASE2","title":"Neoadjuvant Chemotherapy Combined With PD-1 + Radical Radiotherapy in Locally Advanced Cervical Cancer","status":"RECRUITING","sponsor":"Shanghai Jiao Tong University Affiliated Sixth People's Hospital","startDate":"2023-08-01","conditions":"Neoadjuvant Chemotherapy, PD-1 Antibody, Radiotherapy","enrollment":36},{"nctId":"NCT06516445","phase":"PHASE2","title":"SCRT Followed by Camrelizumab Combined With Fluzoparib and Chemotherapy as Neoadjuvant Therapy for LARC","status":"RECRUITING","sponsor":"Huazhong University of Science and Technology","startDate":"2023-06-28","conditions":"Colorectal Cancer","enrollment":33},{"nctId":"NCT06086457","phase":"PHASE3","title":"PD-1 Inhibitor Plus Chemotherapy With or Without Radiotherapy in Patients With Metastatic Esophageal Cancer","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2024-02-04","conditions":"Esophageal Neoplasms","enrollment":436},{"nctId":"NCT06438627","phase":"PHASE3","title":"Efficacy and Safety of TPC+Apatinib+Camrelizumab vs GP+ Camrelizumab for High-Risk Nasopharyngeal Carcinoma: A Phase 3 Trial","status":"RECRUITING","sponsor":"XIANG YANQUN","startDate":"2024-05-30","conditions":"Nasopharyngeal Carcinoma","enrollment":164},{"nctId":"NCT04715633","phase":"PHASE2","title":"PD-1 Inhibitors Combined With VEGF Inhibitors for Locally Advanced dMMR/MSI-H Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2020-12-01","conditions":"Colorectal Cancer, Microsatellite Instability High","enrollment":53},{"nctId":"NCT06485466","phase":"PHASE3","title":"TACE Plus Camrelizumab and Apatinib for Unresectable Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Guohui Xu","startDate":"2024-07-01","conditions":"Unresectable Hepatocellular Carcinoma, Transarterial Chemoembolization, Camrelizumab","enrollment":101},{"nctId":"NCT06485271","phase":"","title":"A Real-world Study of Camrelizumab Alone or in Combination With Apatinib/Chemotherapy for Advanced Gastric Cancer","status":"RECRUITING","sponsor":"Changzhi People's Hospital Affiliated to Changzhi Medical College","startDate":"2023-11-01","conditions":"Gastric Cancer, RWS, PD-1 Immunotherapy","enrollment":504},{"nctId":"NCT06339060","phase":"PHASE3","title":"An Organ Preservation Strategies After Chemoradiotherapy Combined With Immunotherapy for Esophageal Cancer (PALACE3).","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2024-05-01","conditions":"Esophageal Cancer","enrollment":356},{"nctId":"NCT06084897","phase":"PHASE2","title":"Radiotherapy in Patients With Metastatic Esophageal Cancer Responding to PD-1 Inhibitor Plus Chemotherapy","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2023-10-16","conditions":"Esophageal Neoplasm Metastatic, Esophageal Cancer Stage IVb","enrollment":120},{"nctId":"NCT06423170","phase":"PHASE2","title":"A Single-arm Phase II Clinical Study of the Efficacy and Safety of Camrelizumab Combined With GEMOX for Unresectable GBCs","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2023-06-01","conditions":"Unresectable Gallbladder Cancer","enrollment":37},{"nctId":"NCT05128201","phase":"PHASE2","title":"Consolidative Radiotherapy Combined With Camrelizumab and Chemotherapy for Oligometastatic Nasopharyngeal Carcinoma","status":"RECRUITING","sponsor":"Jiangxi Provincial Cancer Hospital","startDate":"2021-12-01","conditions":"Oligometastatic Disease","enrollment":63},{"nctId":"NCT06376721","phase":"PHASE1, PHASE2","title":"Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma","status":"RECRUITING","sponsor":"Beijing Tongren Hospital","startDate":"2024-04-14","conditions":"Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type, T-lymphoblastic Lymphoma","enrollment":43},{"nctId":"NCT06376773","phase":"","title":"Neoadjuvant Treatment Based on Gastric Cancer Molecular Subtyping.","status":"COMPLETED","sponsor":"Fujian Medical University","startDate":"2022-06-01","conditions":"Advanced Gastric Cancer, Neoadjuvant Therapy, Multi-omics Analysis","enrollment":234},{"nctId":"NCT05134194","phase":"PHASE3","title":"A Study of Camrelizumab in Combination With Chemotherapy Regimen Comparative Chemotherapy Regimen for Metastatic Triple-negative Breast Cancer","status":"TERMINATED","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2022-01-17","conditions":"Triple Negative Breast Cancer","enrollment":1},{"nctId":"NCT06356701","phase":"PHASE1","title":"Tumor Nutritional Therapy in the First-line Treatment of Stage IV NSCLC","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Dalian Medical University","startDate":"2024-04-15","conditions":"Long-Term Effects Secondary to Cancer Therapy","enrollment":120},{"nctId":"NCT06354530","phase":"PHASE2, PHASE3","title":"A Study of Neoadjuvant Therapy for the Treatment of Patients With Locally Advanced Esophageal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Army Medical Center of PLA","startDate":"2024-03-08","conditions":"Neoadjuvant Therapy, Esophageal Squamous Cell Carcinoma","enrollment":266},{"nctId":"NCT06346808","phase":"PHASE1","title":"Oncolytic Virus Plus Anti-PD1 and Chemotherapy as Preoperative Therapy for Patients With BRPC/LAPC","status":"NOT_YET_RECRUITING","sponsor":"Sichuan University","startDate":"2024-05-01","conditions":"Pancreatic Cancer","enrollment":20},{"nctId":"NCT05798793","phase":"PHASE3","title":"Neoadjuvant Anti-PD-1 Immunotherapy With Chemotherapy in Resectable Locally Advanced Oral Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Hospital of Stomatology, Wuhan University","startDate":"2023-11-21","conditions":"Oral Squamous Cell Carcinoma","enrollment":309},{"nctId":"NCT06335355","phase":"PHASE2, PHASE3","title":"A Phase II/III Study of Adebrelimab in Combination With SHR-8068 and Chemotherapy in Advanced or Metastatic NSCLC Patients","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Shengdi Pharmaceutical Co., Ltd","startDate":"2024-03","conditions":"Non-squamous Non-small Cell Lung Cancer","enrollment":401},{"nctId":"NCT06326736","phase":"EARLY_PHASE1","title":"Study of Neoantigen mRNA Vaccines in Patients With Resectable Pancreatic Cancer","status":"RECRUITING","sponsor":"Jinling Hospital, China","startDate":"2024-04","conditions":"Pancreatic Cancer","enrollment":12},{"nctId":"NCT06032052","phase":"PHASE2","title":"Single-drug Chemotherapy Plus Immunotherapy in Metastatic Non-small Cell Lung Cancer Elderly Patients","status":"RECRUITING","sponsor":"Hubei Cancer Hospital","startDate":"2024-02-01","conditions":"Elderly Patients, Metastatic Lung Cancer","enrollment":49},{"nctId":"NCT06313463","phase":"PHASE3","title":"Study Of Capecitabine Combined With Camrelizumab For Non-pCR TNBC With TLS After Neoadjuvant Chemoterapy","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2024-03","conditions":"Breast Neoplasms","enrollment":375},{"nctId":"NCT06304545","phase":"PHASE2","title":"Treatment of Rectal Cancer With Long-term Concurrent Chemoradiotherapy Combined With Camrelizumab","status":"NOT_YET_RECRUITING","sponsor":"Harbin Medical University","startDate":"2024-03-15","conditions":"Rectal Cancer","enrollment":48},{"nctId":"NCT05011227","phase":"PHASE2","title":"Camrelizumab and Chemotherapy Combined With Endoscopic Surgery for Recurrent Nasopharyngeal Carcinoma","status":"RECRUITING","sponsor":"Eye & ENT Hospital of Fudan University","startDate":"2021-08-10","conditions":"Recurrent Nasopharyngeal Carcinoma","enrollment":100},{"nctId":"NCT05999149","phase":"PHASE3","title":"A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01)","status":"RECRUITING","sponsor":"Fudan University","startDate":"2023-08-20","conditions":"TNBC - Triple-Negative Breast Cancer","enrollment":424},{"nctId":"NCT04694183","phase":"PHASE2","title":"The Conversion Therapy of Chemotherapy Plus Camrelizumab in Metastatic Gastric Cancer","status":"COMPLETED","sponsor":"Quan Wang","startDate":"2020-08-17","conditions":"Stomach Neoplasms","enrollment":37}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Camrelizumab and Chemotherapy","genericName":"Camrelizumab and Chemotherapy","companyName":"Yue He, MD","companyId":"yue-he-md","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Camrelizumab is a PD-1 inhibitor that blocks immune checkpoint signaling to restore anti-tumor T-cell activity, used in combination with chemotherapy to enhance cancer cell killing. Used for Nasopharyngeal carcinoma in combination with chemotherapy, Hepatocellular carcinoma in combination with chemotherapy, Esophageal squamous cell carcinoma in combination with chemotherapy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}